MIF and type 2 diabetes mellitus: Although the effect of these SNPs on MIF expression or function remain unknown, enhanced MIF plasma levels in patients with ACS (Muller et al., 2012) and the identification of a high MIF plasma level as a risk factor for adverse coronary events in CAD patients with impaired glucose tolerance or type 2 diabetes mellitus (Makino et al., 2010) may support a pro-inflammatory role of plasma MIF in CAD.